476 related articles for article (PubMed ID: 11337315)
1. Tissue effects of saw palmetto and finasteride: use of biopsy cores for in situ quantification of prostatic androgens.
Marks LS; Hess DL; Dorey FJ; Luz Macairan M; Cruz Santos PB; Tyler VE
Urology; 2001 May; 57(5):999-1005. PubMed ID: 11337315
[TBL] [Abstract][Full Text] [Related]
2. Saw palmetto alters nuclear measurements reflecting DNA content in men with symptomatic BPH: evidence for a possible molecular mechanism.
Veltri RW; Marks LS; Miller MC; Bales WD; Fan J; Macairan ML; Epstein JI; Partin AW
Urology; 2002 Oct; 60(4):617-22. PubMed ID: 12385921
[TBL] [Abstract][Full Text] [Related]
3. Differential effect of finasteride on the tissue androgen concentrations in benign prostatic hyperplasia.
Habib FK; Ross M; Tate R; Chisholm GD
Clin Endocrinol (Oxf); 1997 Feb; 46(2):137-44. PubMed ID: 9135694
[TBL] [Abstract][Full Text] [Related]
4. Effects of long-term treatment with Serenoa repens (Permixon) on the concentrations and regional distribution of androgens and epidermal growth factor in benign prostatic hyperplasia.
Di Silverio F; Monti S; Sciarra A; Varasano PA; Martini C; Lanzara S; D'Eramo G; Di Nicola S; Toscano V
Prostate; 1998 Oct; 37(2):77-83. PubMed ID: 9759701
[TBL] [Abstract][Full Text] [Related]
5. Pharmacological effects of the lipidosterolic extract of Serenoa repens (Permixon) on rat prostate hyperplasia induced by hyperprolactinemia: comparison with finasteride.
Van Coppenolle F; Le Bourhis X; Carpentier F; Delaby G; Cousse H; Raynaud JP; Dupouy JP; Prevarskaya N
Prostate; 2000 Apr; 43(1):49-58. PubMed ID: 10725865
[TBL] [Abstract][Full Text] [Related]
6. Effects of a saw palmetto herbal blend in men with symptomatic benign prostatic hyperplasia.
Marks LS; Partin AW; Epstein JI; Tyler VE; Simon I; Macairan ML; Chan TL; Dorey FJ; Garris JB; Veltri RW; Santos PB; Stonebrook KA; deKernion JB
J Urol; 2000 May; 163(5):1451-6. PubMed ID: 10751856
[TBL] [Abstract][Full Text] [Related]
7. Does long-term finasteride therapy affect the histologic features of benign prostatic tissue and prostate cancer on needle biopsy? PLESS Study Group. Proscar Long-Term Efficacy and Safety Study.
Yang XJ; Lecksell K; Short K; Gottesman J; Peterson L; Bannow J; Schellhammer PF; Fitch WP; Hodge GB; Parra R; Rouse S; Waldstreicher J; Epstein JI
Urology; 1999 Apr; 53(4):696-700. PubMed ID: 10197843
[TBL] [Abstract][Full Text] [Related]
8. Dihydrotestosterone and the concept of 5alpha-reductase inhibition in human benign prostatic hyperplasia.
Bartsch G; Rittmaster RS; Klocker H
Eur Urol; 2000 Apr; 37(4):367-80. PubMed ID: 10765065
[TBL] [Abstract][Full Text] [Related]
9. Effect of dutasteride on intraprostatic androgen levels in men with benign prostatic hyperplasia or prostate cancer.
Rittmaster R; Hahn RG; Ray P; Shannon JB; Wurzel R
Urology; 2008 Oct; 72(4):808-12. PubMed ID: 18718641
[TBL] [Abstract][Full Text] [Related]
10. Prostatic tissue testosterone and dihydrotestosterone in African-American and white men.
Marks LS; Hess DL; Dorey FJ; Macairan ML
Urology; 2006 Aug; 68(2):337-41. PubMed ID: 16904448
[TBL] [Abstract][Full Text] [Related]
11. Combined sabal and urtica extract compared with finasteride in men with benign prostatic hyperplasia: analysis of prostate volume and therapeutic outcome.
Sökeland J
BJU Int; 2000 Sep; 86(4):439-42. PubMed ID: 10971268
[TBL] [Abstract][Full Text] [Related]
12. Effects of competitive and noncompetitive 5α-reductase inhibitors on serum and intra-prostatic androgens in beagle dogs.
Zhao XF; Yang Y; Wang W; Qiu Z; Zhang P; Wang B
Chin Med J (Engl); 2013 Feb; 126(4):711-5. PubMed ID: 23422194
[TBL] [Abstract][Full Text] [Related]
13. The effect of finasteride on the prostate gland in men with elevated serum prostate-specific antigen levels.
Cote RJ; Skinner EC; Salem CE; Mertes SJ; Stanczyk FZ; Henderson BE; Pike MC; Ross RK
Br J Cancer; 1998 Aug; 78(3):413-8. PubMed ID: 9703292
[TBL] [Abstract][Full Text] [Related]
14. Effect of finasteride, a 5 alpha-reductase inhibitor on prostate tissue androgens and prostate-specific antigen.
Geller J
J Clin Endocrinol Metab; 1990 Dec; 71(6):1552-5. PubMed ID: 1699965
[TBL] [Abstract][Full Text] [Related]
15. Prevalent decrease of the EGF content in the periurethral zone of BPH tissue induced by treatment with finasteride or flutamide.
Monti S; Sciarra F; Adamo MV; Toscano V; Trotta MC; Martini C; Lanzara S; Silverio FD
J Androl; 1997; 18(5):488-94. PubMed ID: 9349746
[TBL] [Abstract][Full Text] [Related]
16. Comparison of phytotherapy (Permixon) with finasteride in the treatment of benign prostate hyperplasia: a randomized international study of 1,098 patients.
Carraro JC; Raynaud JP; Koch G; Chisholm GD; Di Silverio F; Teillac P; Da Silva FC; Cauquil J; Chopin DK; Hamdy FC; Hanus M; Hauri D; Kalinteris A; Marencak J; Perier A; Perrin P
Prostate; 1996 Oct; 29(4):231-40; discussion 241-2. PubMed ID: 8876706
[TBL] [Abstract][Full Text] [Related]
17. Androgen metabolism in men receiving finasteride before prostatectomy.
Norman RW; Coakes KE; Wright AS; Rittmaster RS
J Urol; 1993 Nov; 150(5 Pt 2):1736-9. PubMed ID: 7692110
[TBL] [Abstract][Full Text] [Related]
18. Comment on the appropriateness of The Prostate publishing a trial comparing Permixon to finasteride without a placebo control group.
Gillenwater JY
Prostate; 1998 Nov; 37(3):194. PubMed ID: 9792137
[No Abstract] [Full Text] [Related]
19. [Hormonal therapy for benign prostatic hyperplasia].
Sakai H; Kanetake H
Nihon Rinsho; 2002 Dec; 60 Suppl 11():358-61. PubMed ID: 12599600
[No Abstract] [Full Text] [Related]
20. Androgen metabolism in the prostate of the finasteride-treated, adult rat: a possible explanation for the differential action of testosterone and 5 alpha-dihydrotestosterone during development of the male urogenital tract.
George FW
Endocrinology; 1997 Mar; 138(3):871-7. PubMed ID: 9048585
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
